Amarantus Bioscience Holdings Inc (AMBS)

[Solantey]

I thought this was noteworthy:

"All of the Company’s existing product candidates are in various stages of development and will require extensive additional preclinical and clinical evaluation, regulatory review and approval, significant marketing efforts and substantial investment before they could provide the Company with any revenue. As a result, if Amarantus does not successfully develop, achieve regulatory approval, and commercialize the LymPro Test, Eltoprazine and/or MANF,it will be unable to generate any revenue for many years,if at all.'

"The Company does not anticipate that it will generate revenue for several years, at the earliest, or that it will achieve profitability for at least several years after generating material revenue, if at all."

"If the company is unable to generate revenue, Amarantus will not become profitable,and may be unable to continue its operations."